Medical Care
Pharmaceutical CMO and CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Nov 05, 24
- ID: 660571
- Pages: 159
- Figures: 244
- Views: 17
A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.
The global market for Pharmaceutical CMO and CDMO was estimated to be worth US$ 128270 million in 2023 and is forecast to a readjusted size of US$ 217220 million by 2030 with a CAGR of 7.7% during the forecast period 2024-2030
The market driver is consistent development of blockbuster pharmaceuticals, increasing production outsourcing by pharmaceuticals companies. The increasing outsourcing trend in the pharmaceutical industry demonstrates the success of this business model, as CDMOs are increasingly becoming integral parts of pharmaceutical companies’ value chains.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical CMO and CDMO, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pharmaceutical CMO and CDMO by region & country, by Type, and by Application.
The Pharmaceutical CMO and CDMO market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical CMO and CDMO.
Market Segmentation
By Company
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Segment by Type:
API CMO and CDMO
FDF CMO and CDMO
Packaging CMO
Clinical CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pharmaceutical CMO and CDMO manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pharmaceutical CMO and CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pharmaceutical CMO and CDMO in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Pharmaceutical CMO and CDMO was estimated to be worth US$ 128270 million in 2023 and is forecast to a readjusted size of US$ 217220 million by 2030 with a CAGR of 7.7% during the forecast period 2024-2030
The market driver is consistent development of blockbuster pharmaceuticals, increasing production outsourcing by pharmaceuticals companies. The increasing outsourcing trend in the pharmaceutical industry demonstrates the success of this business model, as CDMOs are increasingly becoming integral parts of pharmaceutical companies’ value chains.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical CMO and CDMO, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pharmaceutical CMO and CDMO by region & country, by Type, and by Application.
The Pharmaceutical CMO and CDMO market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical CMO and CDMO.
Market Segmentation
By Company
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Segment by Type:
API CMO and CDMO
FDF CMO and CDMO
Packaging CMO
Clinical CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pharmaceutical CMO and CDMO manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pharmaceutical CMO and CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pharmaceutical CMO and CDMO in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Pharmaceutical CMO and CDMO Product Introduction
1.2 Global Pharmaceutical CMO and CDMO Market Size Forecast
1.3 Pharmaceutical CMO and CDMO Market Trends & Drivers
1.3.1 Pharmaceutical CMO and CDMO Industry Trends
1.3.2 Pharmaceutical CMO and CDMO Market Drivers & Opportunity
1.3.3 Pharmaceutical CMO and CDMO Market Challenges
1.3.4 Pharmaceutical CMO and CDMO Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Pharmaceutical CMO and CDMO Players Revenue Ranking (2023)
2.2 Global Pharmaceutical CMO and CDMO Revenue by Company (2019-2024)
2.3 Key Companies Pharmaceutical CMO and CDMO Manufacturing Base Distribution and Headquarters
2.4 Key Companies Pharmaceutical CMO and CDMO Product Offered
2.5 Key Companies Time to Begin Mass Production of Pharmaceutical CMO and CDMO
2.6 Pharmaceutical CMO and CDMO Market Competitive Analysis
2.6.1 Pharmaceutical CMO and CDMO Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Pharmaceutical CMO and CDMO Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical CMO and CDMO as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 API CMO and CDMO
3.1.2 FDF CMO and CDMO
3.1.3 Packaging CMO
3.1.4 Clinical CDMO
3.2 Global Pharmaceutical CMO and CDMO Sales Value by Type
3.2.1 Global Pharmaceutical CMO and CDMO Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Pharmaceutical CMO and CDMO Sales Value, by Type (2019-2030)
3.2.3 Global Pharmaceutical CMO and CDMO Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical Company
4.1.2 Biotechnology Company
4.1.3 Other
4.2 Global Pharmaceutical CMO and CDMO Sales Value by Application
4.2.1 Global Pharmaceutical CMO and CDMO Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Pharmaceutical CMO and CDMO Sales Value, by Application (2019-2030)
4.2.3 Global Pharmaceutical CMO and CDMO Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Pharmaceutical CMO and CDMO Sales Value by Region
5.1.1 Global Pharmaceutical CMO and CDMO Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Pharmaceutical CMO and CDMO Sales Value by Region (2019-2024)
5.1.3 Global Pharmaceutical CMO and CDMO Sales Value by Region (2025-2030)
5.1.4 Global Pharmaceutical CMO and CDMO Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Pharmaceutical CMO and CDMO Sales Value, 2019-2030
5.2.2 North America Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Pharmaceutical CMO and CDMO Sales Value, 2019-2030
5.3.2 Europe Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Pharmaceutical CMO and CDMO Sales Value, 2019-2030
5.4.2 Asia Pacific Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Pharmaceutical CMO and CDMO Sales Value, 2019-2030
5.5.2 South America Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Pharmaceutical CMO and CDMO Sales Value, 2019-2030
5.6.2 Middle East & Africa Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value
6.3 United States
6.3.1 United States Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.3.2 United States Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.4.2 Europe Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.5.2 China Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.5.3 China Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.6.2 Japan Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.7.2 South Korea Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.8.2 Southeast Asia Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.9.2 India Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.9.3 India Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Lonza
7.1.1 Lonza Profile
7.1.2 Lonza Main Business
7.1.3 Lonza Pharmaceutical CMO and CDMO Products, Services and Solutions
7.1.4 Lonza Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.1.5 Lonza Recent Developments
7.2 Catalent
7.2.1 Catalent Profile
7.2.2 Catalent Main Business
7.2.3 Catalent Pharmaceutical CMO and CDMO Products, Services and Solutions
7.2.4 Catalent Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.2.5 Catalent Recent Developments
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Profile
7.3.2 Thermo Fisher Scientific Main Business
7.3.3 Thermo Fisher Scientific Pharmaceutical CMO and CDMO Products, Services and Solutions
7.3.4 Thermo Fisher Scientific Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.3.5 Samsung Biologics Recent Developments
7.4 Samsung Biologics
7.4.1 Samsung Biologics Profile
7.4.2 Samsung Biologics Main Business
7.4.3 Samsung Biologics Pharmaceutical CMO and CDMO Products, Services and Solutions
7.4.4 Samsung Biologics Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.4.5 Samsung Biologics Recent Developments
7.5 Fareva
7.5.1 Fareva Profile
7.5.2 Fareva Main Business
7.5.3 Fareva Pharmaceutical CMO and CDMO Products, Services and Solutions
7.5.4 Fareva Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.5.5 Fareva Recent Developments
7.6 WuXi AppTech
7.6.1 WuXi AppTech Profile
7.6.2 WuXi AppTech Main Business
7.6.3 WuXi AppTech Pharmaceutical CMO and CDMO Products, Services and Solutions
7.6.4 WuXi AppTech Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.6.5 WuXi AppTech Recent Developments
7.7 WuXi Biologics
7.7.1 WuXi Biologics Profile
7.7.2 WuXi Biologics Main Business
7.7.3 WuXi Biologics Pharmaceutical CMO and CDMO Products, Services and Solutions
7.7.4 WuXi Biologics Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.7.5 WuXi Biologics Recent Developments
7.8 Siegfried
7.8.1 Siegfried Profile
7.8.2 Siegfried Main Business
7.8.3 Siegfried Pharmaceutical CMO and CDMO Products, Services and Solutions
7.8.4 Siegfried Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.8.5 Siegfried Recent Developments
7.9 FUJIFILM Diosynth Biotechnologies
7.9.1 FUJIFILM Diosynth Biotechnologies Profile
7.9.2 FUJIFILM Diosynth Biotechnologies Main Business
7.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO Products, Services and Solutions
7.9.4 FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
7.10 Asymchem
7.10.1 Asymchem Profile
7.10.2 Asymchem Main Business
7.10.3 Asymchem Pharmaceutical CMO and CDMO Products, Services and Solutions
7.10.4 Asymchem Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.10.5 Asymchem Recent Developments
7.11 Pfizer CentreOne
7.11.1 Pfizer CentreOne Profile
7.11.2 Pfizer CentreOne Main Business
7.11.3 Pfizer CentreOne Pharmaceutical CMO and CDMO Products, Services and Solutions
7.11.4 Pfizer CentreOne Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.11.5 Pfizer CentreOne Recent Developments
7.12 Delpharm
7.12.1 Delpharm Profile
7.12.2 Delpharm Main Business
7.12.3 Delpharm Pharmaceutical CMO and CDMO Products, Services and Solutions
7.12.4 Delpharm Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.12.5 Delpharm Recent Developments
7.13 Recipharm
7.13.1 Recipharm Profile
7.13.2 Recipharm Main Business
7.13.3 Recipharm Pharmaceutical CMO and CDMO Products, Services and Solutions
7.13.4 Recipharm Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.13.5 Recipharm Recent Developments
7.14 AGC Pharma Chemicals
7.14.1 AGC Pharma Chemicals Profile
7.14.2 AGC Pharma Chemicals Main Business
7.14.3 AGC Pharma Chemicals Pharmaceutical CMO and CDMO Products, Services and Solutions
7.14.4 AGC Pharma Chemicals Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.14.5 AGC Pharma Chemicals Recent Developments
7.15 Boehringer Ingelheim
7.15.1 Boehringer Ingelheim Profile
7.15.2 Boehringer Ingelheim Main Business
7.15.3 Boehringer Ingelheim Pharmaceutical CMO and CDMO Products, Services and Solutions
7.15.4 Boehringer Ingelheim Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.15.5 Boehringer Ingelheim Recent Developments
7.16 Vetter
7.16.1 Vetter Profile
7.16.2 Vetter Main Business
7.16.3 Vetter Pharmaceutical CMO and CDMO Products, Services and Solutions
7.16.4 Vetter Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.16.5 Vetter Recent Developments
7.17 Curia
7.17.1 Curia Profile
7.17.2 Curia Main Business
7.17.3 Curia Pharmaceutical CMO and CDMO Products, Services and Solutions
7.17.4 Curia Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.17.5 Curia Recent Developments
7.18 Aenova
7.18.1 Aenova Profile
7.18.2 Aenova Main Business
7.18.3 Aenova Pharmaceutical CMO and CDMO Products, Services and Solutions
7.18.4 Aenova Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.18.5 Aenova Recent Developments
7.19 Porton
7.19.1 Porton Profile
7.19.2 Porton Main Business
7.19.3 Porton Pharmaceutical CMO and CDMO Products, Services and Solutions
7.19.4 Porton Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.19.5 Porton Recent Developments
7.20 Piramal
7.20.1 Piramal Profile
7.20.2 Piramal Main Business
7.20.3 Piramal Pharmaceutical CMO and CDMO Products, Services and Solutions
7.20.4 Piramal Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.20.5 Piramal Recent Developments
7.21 Strides Pharma
7.21.1 Strides Pharma Profile
7.21.2 Strides Pharma Main Business
7.21.3 Strides Pharma Pharmaceutical CMO and CDMO Products, Services and Solutions
7.21.4 Strides Pharma Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.21.5 Strides Pharma Recent Developments
7.22 NextPharma
7.22.1 NextPharma Profile
7.22.2 NextPharma Main Business
7.22.3 NextPharma Pharmaceutical CMO and CDMO Products, Services and Solutions
7.22.4 NextPharma Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.22.5 NextPharma Recent Developments
7.23 Famar
7.23.1 Famar Profile
7.23.2 Famar Main Business
7.23.3 Famar Pharmaceutical CMO and CDMO Products, Services and Solutions
7.23.4 Famar Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.23.5 Famar Recent Developments
7.24 Jubilant
7.24.1 Jubilant Profile
7.24.2 Jubilant Main Business
7.24.3 Jubilant Pharmaceutical CMO and CDMO Products, Services and Solutions
7.24.4 Jubilant Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.24.5 Jubilant Recent Developments
7.25 Alcami
7.25.1 Alcami Profile
7.25.2 Alcami Main Business
7.25.3 Alcami Pharmaceutical CMO and CDMO Products, Services and Solutions
7.25.4 Alcami Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.25.5 Alcami Recent Developments
7.26 Euroapi
7.26.1 Euroapi Profile
7.26.2 Euroapi Main Business
7.26.3 Euroapi Pharmaceutical CMO and CDMO Products, Services and Solutions
7.26.4 Euroapi Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.26.5 Euroapi Recent Developments
7.27 Eurofins
7.27.1 Eurofins Profile
7.27.2 Eurofins Main Business
7.27.3 Eurofins Pharmaceutical CMO and CDMO Products, Services and Solutions
7.27.4 Eurofins Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.27.5 Eurofins Recent Developments
7.28 Avid Bioservices
7.28.1 Avid Bioservices Profile
7.28.2 Avid Bioservices Main Business
7.28.3 Avid Bioservices Pharmaceutical CMO and CDMO Products, Services and Solutions
7.28.4 Avid Bioservices Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.28.5 Avid Bioservices Recent Developments
7.29 BioVectra
7.29.1 BioVectra Profile
7.29.2 BioVectra Main Business
7.29.3 BioVectra Pharmaceutical CMO and CDMO Products, Services and Solutions
7.29.4 BioVectra Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.29.5 BioVectra Recent Developments
7.30 CPL
7.30.1 CPL Profile
7.30.2 CPL Main Business
7.30.3 CPL Pharmaceutical CMO and CDMO Products, Services and Solutions
7.30.4 CPL Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.30.5 CPL Recent Developments
8 Industry Chain Analysis
8.1 Pharmaceutical CMO and CDMO Industrial Chain
8.2 Pharmaceutical CMO and CDMO Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Pharmaceutical CMO and CDMO Sales Model
8.5.2 Sales Channel
8.5.3 Pharmaceutical CMO and CDMO Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Pharmaceutical CMO and CDMO Product Introduction
1.2 Global Pharmaceutical CMO and CDMO Market Size Forecast
1.3 Pharmaceutical CMO and CDMO Market Trends & Drivers
1.3.1 Pharmaceutical CMO and CDMO Industry Trends
1.3.2 Pharmaceutical CMO and CDMO Market Drivers & Opportunity
1.3.3 Pharmaceutical CMO and CDMO Market Challenges
1.3.4 Pharmaceutical CMO and CDMO Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Pharmaceutical CMO and CDMO Players Revenue Ranking (2023)
2.2 Global Pharmaceutical CMO and CDMO Revenue by Company (2019-2024)
2.3 Key Companies Pharmaceutical CMO and CDMO Manufacturing Base Distribution and Headquarters
2.4 Key Companies Pharmaceutical CMO and CDMO Product Offered
2.5 Key Companies Time to Begin Mass Production of Pharmaceutical CMO and CDMO
2.6 Pharmaceutical CMO and CDMO Market Competitive Analysis
2.6.1 Pharmaceutical CMO and CDMO Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Pharmaceutical CMO and CDMO Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical CMO and CDMO as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 API CMO and CDMO
3.1.2 FDF CMO and CDMO
3.1.3 Packaging CMO
3.1.4 Clinical CDMO
3.2 Global Pharmaceutical CMO and CDMO Sales Value by Type
3.2.1 Global Pharmaceutical CMO and CDMO Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Pharmaceutical CMO and CDMO Sales Value, by Type (2019-2030)
3.2.3 Global Pharmaceutical CMO and CDMO Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical Company
4.1.2 Biotechnology Company
4.1.3 Other
4.2 Global Pharmaceutical CMO and CDMO Sales Value by Application
4.2.1 Global Pharmaceutical CMO and CDMO Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Pharmaceutical CMO and CDMO Sales Value, by Application (2019-2030)
4.2.3 Global Pharmaceutical CMO and CDMO Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Pharmaceutical CMO and CDMO Sales Value by Region
5.1.1 Global Pharmaceutical CMO and CDMO Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Pharmaceutical CMO and CDMO Sales Value by Region (2019-2024)
5.1.3 Global Pharmaceutical CMO and CDMO Sales Value by Region (2025-2030)
5.1.4 Global Pharmaceutical CMO and CDMO Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Pharmaceutical CMO and CDMO Sales Value, 2019-2030
5.2.2 North America Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Pharmaceutical CMO and CDMO Sales Value, 2019-2030
5.3.2 Europe Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Pharmaceutical CMO and CDMO Sales Value, 2019-2030
5.4.2 Asia Pacific Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Pharmaceutical CMO and CDMO Sales Value, 2019-2030
5.5.2 South America Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Pharmaceutical CMO and CDMO Sales Value, 2019-2030
5.6.2 Middle East & Africa Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value
6.3 United States
6.3.1 United States Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.3.2 United States Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.4.2 Europe Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.5.2 China Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.5.3 China Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.6.2 Japan Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.7.2 South Korea Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.8.2 Southeast Asia Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Pharmaceutical CMO and CDMO Sales Value, 2019-2030
6.9.2 India Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
6.9.3 India Pharmaceutical CMO and CDMO Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Lonza
7.1.1 Lonza Profile
7.1.2 Lonza Main Business
7.1.3 Lonza Pharmaceutical CMO and CDMO Products, Services and Solutions
7.1.4 Lonza Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.1.5 Lonza Recent Developments
7.2 Catalent
7.2.1 Catalent Profile
7.2.2 Catalent Main Business
7.2.3 Catalent Pharmaceutical CMO and CDMO Products, Services and Solutions
7.2.4 Catalent Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.2.5 Catalent Recent Developments
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Profile
7.3.2 Thermo Fisher Scientific Main Business
7.3.3 Thermo Fisher Scientific Pharmaceutical CMO and CDMO Products, Services and Solutions
7.3.4 Thermo Fisher Scientific Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.3.5 Samsung Biologics Recent Developments
7.4 Samsung Biologics
7.4.1 Samsung Biologics Profile
7.4.2 Samsung Biologics Main Business
7.4.3 Samsung Biologics Pharmaceutical CMO and CDMO Products, Services and Solutions
7.4.4 Samsung Biologics Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.4.5 Samsung Biologics Recent Developments
7.5 Fareva
7.5.1 Fareva Profile
7.5.2 Fareva Main Business
7.5.3 Fareva Pharmaceutical CMO and CDMO Products, Services and Solutions
7.5.4 Fareva Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.5.5 Fareva Recent Developments
7.6 WuXi AppTech
7.6.1 WuXi AppTech Profile
7.6.2 WuXi AppTech Main Business
7.6.3 WuXi AppTech Pharmaceutical CMO and CDMO Products, Services and Solutions
7.6.4 WuXi AppTech Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.6.5 WuXi AppTech Recent Developments
7.7 WuXi Biologics
7.7.1 WuXi Biologics Profile
7.7.2 WuXi Biologics Main Business
7.7.3 WuXi Biologics Pharmaceutical CMO and CDMO Products, Services and Solutions
7.7.4 WuXi Biologics Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.7.5 WuXi Biologics Recent Developments
7.8 Siegfried
7.8.1 Siegfried Profile
7.8.2 Siegfried Main Business
7.8.3 Siegfried Pharmaceutical CMO and CDMO Products, Services and Solutions
7.8.4 Siegfried Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.8.5 Siegfried Recent Developments
7.9 FUJIFILM Diosynth Biotechnologies
7.9.1 FUJIFILM Diosynth Biotechnologies Profile
7.9.2 FUJIFILM Diosynth Biotechnologies Main Business
7.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO Products, Services and Solutions
7.9.4 FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
7.10 Asymchem
7.10.1 Asymchem Profile
7.10.2 Asymchem Main Business
7.10.3 Asymchem Pharmaceutical CMO and CDMO Products, Services and Solutions
7.10.4 Asymchem Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.10.5 Asymchem Recent Developments
7.11 Pfizer CentreOne
7.11.1 Pfizer CentreOne Profile
7.11.2 Pfizer CentreOne Main Business
7.11.3 Pfizer CentreOne Pharmaceutical CMO and CDMO Products, Services and Solutions
7.11.4 Pfizer CentreOne Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.11.5 Pfizer CentreOne Recent Developments
7.12 Delpharm
7.12.1 Delpharm Profile
7.12.2 Delpharm Main Business
7.12.3 Delpharm Pharmaceutical CMO and CDMO Products, Services and Solutions
7.12.4 Delpharm Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.12.5 Delpharm Recent Developments
7.13 Recipharm
7.13.1 Recipharm Profile
7.13.2 Recipharm Main Business
7.13.3 Recipharm Pharmaceutical CMO and CDMO Products, Services and Solutions
7.13.4 Recipharm Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.13.5 Recipharm Recent Developments
7.14 AGC Pharma Chemicals
7.14.1 AGC Pharma Chemicals Profile
7.14.2 AGC Pharma Chemicals Main Business
7.14.3 AGC Pharma Chemicals Pharmaceutical CMO and CDMO Products, Services and Solutions
7.14.4 AGC Pharma Chemicals Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.14.5 AGC Pharma Chemicals Recent Developments
7.15 Boehringer Ingelheim
7.15.1 Boehringer Ingelheim Profile
7.15.2 Boehringer Ingelheim Main Business
7.15.3 Boehringer Ingelheim Pharmaceutical CMO and CDMO Products, Services and Solutions
7.15.4 Boehringer Ingelheim Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.15.5 Boehringer Ingelheim Recent Developments
7.16 Vetter
7.16.1 Vetter Profile
7.16.2 Vetter Main Business
7.16.3 Vetter Pharmaceutical CMO and CDMO Products, Services and Solutions
7.16.4 Vetter Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.16.5 Vetter Recent Developments
7.17 Curia
7.17.1 Curia Profile
7.17.2 Curia Main Business
7.17.3 Curia Pharmaceutical CMO and CDMO Products, Services and Solutions
7.17.4 Curia Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.17.5 Curia Recent Developments
7.18 Aenova
7.18.1 Aenova Profile
7.18.2 Aenova Main Business
7.18.3 Aenova Pharmaceutical CMO and CDMO Products, Services and Solutions
7.18.4 Aenova Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.18.5 Aenova Recent Developments
7.19 Porton
7.19.1 Porton Profile
7.19.2 Porton Main Business
7.19.3 Porton Pharmaceutical CMO and CDMO Products, Services and Solutions
7.19.4 Porton Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.19.5 Porton Recent Developments
7.20 Piramal
7.20.1 Piramal Profile
7.20.2 Piramal Main Business
7.20.3 Piramal Pharmaceutical CMO and CDMO Products, Services and Solutions
7.20.4 Piramal Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.20.5 Piramal Recent Developments
7.21 Strides Pharma
7.21.1 Strides Pharma Profile
7.21.2 Strides Pharma Main Business
7.21.3 Strides Pharma Pharmaceutical CMO and CDMO Products, Services and Solutions
7.21.4 Strides Pharma Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.21.5 Strides Pharma Recent Developments
7.22 NextPharma
7.22.1 NextPharma Profile
7.22.2 NextPharma Main Business
7.22.3 NextPharma Pharmaceutical CMO and CDMO Products, Services and Solutions
7.22.4 NextPharma Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.22.5 NextPharma Recent Developments
7.23 Famar
7.23.1 Famar Profile
7.23.2 Famar Main Business
7.23.3 Famar Pharmaceutical CMO and CDMO Products, Services and Solutions
7.23.4 Famar Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.23.5 Famar Recent Developments
7.24 Jubilant
7.24.1 Jubilant Profile
7.24.2 Jubilant Main Business
7.24.3 Jubilant Pharmaceutical CMO and CDMO Products, Services and Solutions
7.24.4 Jubilant Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.24.5 Jubilant Recent Developments
7.25 Alcami
7.25.1 Alcami Profile
7.25.2 Alcami Main Business
7.25.3 Alcami Pharmaceutical CMO and CDMO Products, Services and Solutions
7.25.4 Alcami Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.25.5 Alcami Recent Developments
7.26 Euroapi
7.26.1 Euroapi Profile
7.26.2 Euroapi Main Business
7.26.3 Euroapi Pharmaceutical CMO and CDMO Products, Services and Solutions
7.26.4 Euroapi Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.26.5 Euroapi Recent Developments
7.27 Eurofins
7.27.1 Eurofins Profile
7.27.2 Eurofins Main Business
7.27.3 Eurofins Pharmaceutical CMO and CDMO Products, Services and Solutions
7.27.4 Eurofins Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.27.5 Eurofins Recent Developments
7.28 Avid Bioservices
7.28.1 Avid Bioservices Profile
7.28.2 Avid Bioservices Main Business
7.28.3 Avid Bioservices Pharmaceutical CMO and CDMO Products, Services and Solutions
7.28.4 Avid Bioservices Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.28.5 Avid Bioservices Recent Developments
7.29 BioVectra
7.29.1 BioVectra Profile
7.29.2 BioVectra Main Business
7.29.3 BioVectra Pharmaceutical CMO and CDMO Products, Services and Solutions
7.29.4 BioVectra Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.29.5 BioVectra Recent Developments
7.30 CPL
7.30.1 CPL Profile
7.30.2 CPL Main Business
7.30.3 CPL Pharmaceutical CMO and CDMO Products, Services and Solutions
7.30.4 CPL Pharmaceutical CMO and CDMO Revenue (US$ Million) & (2019-2024)
7.30.5 CPL Recent Developments
8 Industry Chain Analysis
8.1 Pharmaceutical CMO and CDMO Industrial Chain
8.2 Pharmaceutical CMO and CDMO Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Pharmaceutical CMO and CDMO Sales Model
8.5.2 Sales Channel
8.5.3 Pharmaceutical CMO and CDMO Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Pharmaceutical CMO and CDMO Market Trends
Table 2. Pharmaceutical CMO and CDMO Market Drivers & Opportunity
Table 3. Pharmaceutical CMO and CDMO Market Challenges
Table 4. Pharmaceutical CMO and CDMO Market Restraints
Table 5. Global Pharmaceutical CMO and CDMO Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Pharmaceutical CMO and CDMO Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Pharmaceutical CMO and CDMO Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Pharmaceutical CMO and CDMO Product Type
Table 9. Key Companies Time to Begin Mass Production of Pharmaceutical CMO and CDMO
Table 10. Global Pharmaceutical CMO and CDMO Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical CMO and CDMO as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Pharmaceutical CMO and CDMO Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Pharmaceutical CMO and CDMO Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Pharmaceutical CMO and CDMO Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Pharmaceutical CMO and CDMO Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Pharmaceutical CMO and CDMO Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Pharmaceutical CMO and CDMO Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Pharmaceutical CMO and CDMO Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Pharmaceutical CMO and CDMO Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Pharmaceutical CMO and CDMO Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Pharmaceutical CMO and CDMO Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Pharmaceutical CMO and CDMO Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Pharmaceutical CMO and CDMO Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Pharmaceutical CMO and CDMO Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Pharmaceutical CMO and CDMO Sales Value by Region (2019-2024) & (%)
Table 27. Global Pharmaceutical CMO and CDMO Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value, (2025-2030) & (US$ Million)
Table 31. Lonza Basic Information List
Table 32. Lonza Description and Business Overview
Table 33. Lonza Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 34. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Lonza (2019-2024)
Table 35. Lonza Recent Developments
Table 36. Catalent Basic Information List
Table 37. Catalent Description and Business Overview
Table 38. Catalent Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 39. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Catalent (2019-2024)
Table 40. Catalent Recent Developments
Table 41. Thermo Fisher Scientific Basic Information List
Table 42. Thermo Fisher Scientific Description and Business Overview
Table 43. Thermo Fisher Scientific Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 44. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Thermo Fisher Scientific (2019-2024)
Table 45. Thermo Fisher Scientific Recent Developments
Table 46. Samsung Biologics Basic Information List
Table 47. Samsung Biologics Description and Business Overview
Table 48. Samsung Biologics Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 49. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Samsung Biologics (2019-2024)
Table 50. Samsung Biologics Recent Developments
Table 51. Fareva Basic Information List
Table 52. Fareva Description and Business Overview
Table 53. Fareva Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 54. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Fareva (2019-2024)
Table 55. Fareva Recent Developments
Table 56. WuXi AppTech Basic Information List
Table 57. WuXi AppTech Description and Business Overview
Table 58. WuXi AppTech Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 59. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of WuXi AppTech (2019-2024)
Table 60. WuXi AppTech Recent Developments
Table 61. WuXi Biologics Basic Information List
Table 62. WuXi Biologics Description and Business Overview
Table 63. WuXi Biologics Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 64. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of WuXi Biologics (2019-2024)
Table 65. WuXi Biologics Recent Developments
Table 66. Siegfried Basic Information List
Table 67. Siegfried Description and Business Overview
Table 68. Siegfried Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 69. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Siegfried (2019-2024)
Table 70. Siegfried Recent Developments
Table 71. FUJIFILM Diosynth Biotechnologies Basic Information List
Table 72. FUJIFILM Diosynth Biotechnologies Description and Business Overview
Table 73. FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 74. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of FUJIFILM Diosynth Biotechnologies (2019-2024)
Table 75. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 76. Asymchem Basic Information List
Table 77. Asymchem Description and Business Overview
Table 78. Asymchem Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 79. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Asymchem (2019-2024)
Table 80. Asymchem Recent Developments
Table 81. Pfizer CentreOne Basic Information List
Table 82. Pfizer CentreOne Description and Business Overview
Table 83. Pfizer CentreOne Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 84. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Pfizer CentreOne (2019-2024)
Table 85. Pfizer CentreOne Recent Developments
Table 86. Delpharm Basic Information List
Table 87. Delpharm Description and Business Overview
Table 88. Delpharm Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 89. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Delpharm (2019-2024)
Table 90. Delpharm Recent Developments
Table 91. Recipharm Basic Information List
Table 92. Recipharm Description and Business Overview
Table 93. Recipharm Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 94. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Recipharm (2019-2024)
Table 95. Recipharm Recent Developments
Table 96. AGC Pharma Chemicals Basic Information List
Table 97. AGC Pharma Chemicals Description and Business Overview
Table 98. AGC Pharma Chemicals Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 99. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of AGC Pharma Chemicals (2019-2024)
Table 100. AGC Pharma Chemicals Recent Developments
Table 101. Boehringer Ingelheim Basic Information List
Table 102. Boehringer Ingelheim Description and Business Overview
Table 103. Boehringer Ingelheim Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 104. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Boehringer Ingelheim (2019-2024)
Table 105. Boehringer Ingelheim Recent Developments
Table 106. Vetter Basic Information List
Table 107. Vetter Description and Business Overview
Table 108. Vetter Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 109. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Vetter (2019-2024)
Table 110. Vetter Recent Developments
Table 111. Curia Basic Information List
Table 112. Curia Description and Business Overview
Table 113. Curia Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 114. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Curia (2019-2024)
Table 115. Curia Recent Developments
Table 116. Aenova Basic Information List
Table 117. Aenova Description and Business Overview
Table 118. Aenova Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 119. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Aenova (2019-2024)
Table 120. Aenova Recent Developments
Table 121. Porton Basic Information List
Table 122. Porton Description and Business Overview
Table 123. Porton Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 124. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Porton (2019-2024)
Table 125. Porton Recent Developments
Table 126. Piramal Basic Information List
Table 127. Piramal Description and Business Overview
Table 128. Piramal Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 129. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Piramal (2019-2024)
Table 130. Piramal Recent Developments
Table 131. Strides Pharma Basic Information List
Table 132. Strides Pharma Description and Business Overview
Table 133. Strides Pharma Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 134. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Strides Pharma (2019-2024)
Table 135. Strides Pharma Recent Developments
Table 136. NextPharma Basic Information List
Table 137. NextPharma Description and Business Overview
Table 138. NextPharma Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 139. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of NextPharma (2019-2024)
Table 140. NextPharma Recent Developments
Table 141. Famar Basic Information List
Table 142. Famar Description and Business Overview
Table 143. Famar Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 144. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Famar (2019-2024)
Table 145. Famar Recent Developments
Table 146. Jubilant Basic Information List
Table 147. Jubilant Description and Business Overview
Table 148. Jubilant Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 149. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Jubilant (2019-2024)
Table 150. Jubilant Recent Developments
Table 151. Alcami Basic Information List
Table 152. Alcami Description and Business Overview
Table 153. Alcami Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 154. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Alcami (2019-2024)
Table 155. Alcami Recent Developments
Table 156. Euroapi Basic Information List
Table 157. Euroapi Description and Business Overview
Table 158. Euroapi Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 159. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Euroapi (2019-2024)
Table 160. Euroapi Recent Developments
Table 161. Eurofins Basic Information List
Table 162. Eurofins Description and Business Overview
Table 163. Eurofins Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 164. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Eurofins (2019-2024)
Table 165. Eurofins Recent Developments
Table 166. Avid Bioservices Basic Information List
Table 167. Avid Bioservices Description and Business Overview
Table 168. Avid Bioservices Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 169. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Avid Bioservices (2019-2024)
Table 170. Avid Bioservices Recent Developments
Table 171. BioVectra Basic Information List
Table 172. BioVectra Description and Business Overview
Table 173. BioVectra Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 174. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of BioVectra (2019-2024)
Table 175. BioVectra Recent Developments
Table 176. CPL Basic Information List
Table 177. CPL Description and Business Overview
Table 178. CPL Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 179. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of CPL (2019-2024)
Table 180. CPL Recent Developments
Table 181. Key Raw Materials Lists
Table 182. Raw Materials Key Suppliers Lists
Table 183. Pharmaceutical CMO and CDMO Downstream Customers
Table 184. Pharmaceutical CMO and CDMO Distributors List
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
Table 188. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Pharmaceutical CMO and CDMO Product Picture
Figure 2. Global Pharmaceutical CMO and CDMO Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 4. Pharmaceutical CMO and CDMO Report Years Considered
Figure 5. Global Pharmaceutical CMO and CDMO Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Pharmaceutical CMO and CDMO Revenue in 2023
Figure 7. Pharmaceutical CMO and CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. API CMO and CDMO Picture
Figure 9. FDF CMO and CDMO Picture
Figure 10. Packaging CMO Picture
Figure 11. Clinical CDMO Picture
Figure 12. Global Pharmaceutical CMO and CDMO Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 13. Global Pharmaceutical CMO and CDMO Sales Value Market Share by Type, 2023 & 2030
Figure 14. Product Picture of Pharmaceutical Company
Figure 15. Product Picture of Biotechnology Company
Figure 16. Product Picture of Other
Figure 17. Global Pharmaceutical CMO and CDMO Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Pharmaceutical CMO and CDMO Sales Value Market Share by Application, 2023 & 2030
Figure 19. North America Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 20. North America Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 22. Europe Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 24. Asia Pacific Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
Figure 25. South America Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 26. South America Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
Figure 27. Middle East & Africa Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 28. Middle East & Africa Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
Figure 29. Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value (%), (2019-2030)
Figure 30. United States Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 31. United States Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 32. United States Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 33. Europe Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 34. Europe Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 35. Europe Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 36. China Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 37. China Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 38. China Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 39. Japan Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 40. Japan Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 41. Japan Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 42. South Korea Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 43. South Korea Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 44. South Korea Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 45. Southeast Asia Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 47. Southeast Asia Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 48. India Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 49. India Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 50. India Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 51. Pharmaceutical CMO and CDMO Industrial Chain
Figure 52. Pharmaceutical CMO and CDMO Manufacturing Cost Structure
Figure 53. Channels of Distribution (Direct Sales, and Distribution)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Table 1. Pharmaceutical CMO and CDMO Market Trends
Table 2. Pharmaceutical CMO and CDMO Market Drivers & Opportunity
Table 3. Pharmaceutical CMO and CDMO Market Challenges
Table 4. Pharmaceutical CMO and CDMO Market Restraints
Table 5. Global Pharmaceutical CMO and CDMO Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Pharmaceutical CMO and CDMO Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Pharmaceutical CMO and CDMO Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Pharmaceutical CMO and CDMO Product Type
Table 9. Key Companies Time to Begin Mass Production of Pharmaceutical CMO and CDMO
Table 10. Global Pharmaceutical CMO and CDMO Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical CMO and CDMO as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Pharmaceutical CMO and CDMO Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Pharmaceutical CMO and CDMO Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Pharmaceutical CMO and CDMO Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Pharmaceutical CMO and CDMO Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Pharmaceutical CMO and CDMO Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Pharmaceutical CMO and CDMO Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Pharmaceutical CMO and CDMO Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Pharmaceutical CMO and CDMO Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Pharmaceutical CMO and CDMO Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Pharmaceutical CMO and CDMO Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Pharmaceutical CMO and CDMO Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Pharmaceutical CMO and CDMO Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Pharmaceutical CMO and CDMO Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Pharmaceutical CMO and CDMO Sales Value by Region (2019-2024) & (%)
Table 27. Global Pharmaceutical CMO and CDMO Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value, (2025-2030) & (US$ Million)
Table 31. Lonza Basic Information List
Table 32. Lonza Description and Business Overview
Table 33. Lonza Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 34. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Lonza (2019-2024)
Table 35. Lonza Recent Developments
Table 36. Catalent Basic Information List
Table 37. Catalent Description and Business Overview
Table 38. Catalent Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 39. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Catalent (2019-2024)
Table 40. Catalent Recent Developments
Table 41. Thermo Fisher Scientific Basic Information List
Table 42. Thermo Fisher Scientific Description and Business Overview
Table 43. Thermo Fisher Scientific Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 44. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Thermo Fisher Scientific (2019-2024)
Table 45. Thermo Fisher Scientific Recent Developments
Table 46. Samsung Biologics Basic Information List
Table 47. Samsung Biologics Description and Business Overview
Table 48. Samsung Biologics Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 49. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Samsung Biologics (2019-2024)
Table 50. Samsung Biologics Recent Developments
Table 51. Fareva Basic Information List
Table 52. Fareva Description and Business Overview
Table 53. Fareva Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 54. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Fareva (2019-2024)
Table 55. Fareva Recent Developments
Table 56. WuXi AppTech Basic Information List
Table 57. WuXi AppTech Description and Business Overview
Table 58. WuXi AppTech Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 59. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of WuXi AppTech (2019-2024)
Table 60. WuXi AppTech Recent Developments
Table 61. WuXi Biologics Basic Information List
Table 62. WuXi Biologics Description and Business Overview
Table 63. WuXi Biologics Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 64. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of WuXi Biologics (2019-2024)
Table 65. WuXi Biologics Recent Developments
Table 66. Siegfried Basic Information List
Table 67. Siegfried Description and Business Overview
Table 68. Siegfried Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 69. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Siegfried (2019-2024)
Table 70. Siegfried Recent Developments
Table 71. FUJIFILM Diosynth Biotechnologies Basic Information List
Table 72. FUJIFILM Diosynth Biotechnologies Description and Business Overview
Table 73. FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 74. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of FUJIFILM Diosynth Biotechnologies (2019-2024)
Table 75. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 76. Asymchem Basic Information List
Table 77. Asymchem Description and Business Overview
Table 78. Asymchem Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 79. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Asymchem (2019-2024)
Table 80. Asymchem Recent Developments
Table 81. Pfizer CentreOne Basic Information List
Table 82. Pfizer CentreOne Description and Business Overview
Table 83. Pfizer CentreOne Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 84. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Pfizer CentreOne (2019-2024)
Table 85. Pfizer CentreOne Recent Developments
Table 86. Delpharm Basic Information List
Table 87. Delpharm Description and Business Overview
Table 88. Delpharm Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 89. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Delpharm (2019-2024)
Table 90. Delpharm Recent Developments
Table 91. Recipharm Basic Information List
Table 92. Recipharm Description and Business Overview
Table 93. Recipharm Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 94. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Recipharm (2019-2024)
Table 95. Recipharm Recent Developments
Table 96. AGC Pharma Chemicals Basic Information List
Table 97. AGC Pharma Chemicals Description and Business Overview
Table 98. AGC Pharma Chemicals Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 99. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of AGC Pharma Chemicals (2019-2024)
Table 100. AGC Pharma Chemicals Recent Developments
Table 101. Boehringer Ingelheim Basic Information List
Table 102. Boehringer Ingelheim Description and Business Overview
Table 103. Boehringer Ingelheim Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 104. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Boehringer Ingelheim (2019-2024)
Table 105. Boehringer Ingelheim Recent Developments
Table 106. Vetter Basic Information List
Table 107. Vetter Description and Business Overview
Table 108. Vetter Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 109. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Vetter (2019-2024)
Table 110. Vetter Recent Developments
Table 111. Curia Basic Information List
Table 112. Curia Description and Business Overview
Table 113. Curia Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 114. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Curia (2019-2024)
Table 115. Curia Recent Developments
Table 116. Aenova Basic Information List
Table 117. Aenova Description and Business Overview
Table 118. Aenova Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 119. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Aenova (2019-2024)
Table 120. Aenova Recent Developments
Table 121. Porton Basic Information List
Table 122. Porton Description and Business Overview
Table 123. Porton Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 124. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Porton (2019-2024)
Table 125. Porton Recent Developments
Table 126. Piramal Basic Information List
Table 127. Piramal Description and Business Overview
Table 128. Piramal Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 129. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Piramal (2019-2024)
Table 130. Piramal Recent Developments
Table 131. Strides Pharma Basic Information List
Table 132. Strides Pharma Description and Business Overview
Table 133. Strides Pharma Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 134. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Strides Pharma (2019-2024)
Table 135. Strides Pharma Recent Developments
Table 136. NextPharma Basic Information List
Table 137. NextPharma Description and Business Overview
Table 138. NextPharma Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 139. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of NextPharma (2019-2024)
Table 140. NextPharma Recent Developments
Table 141. Famar Basic Information List
Table 142. Famar Description and Business Overview
Table 143. Famar Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 144. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Famar (2019-2024)
Table 145. Famar Recent Developments
Table 146. Jubilant Basic Information List
Table 147. Jubilant Description and Business Overview
Table 148. Jubilant Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 149. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Jubilant (2019-2024)
Table 150. Jubilant Recent Developments
Table 151. Alcami Basic Information List
Table 152. Alcami Description and Business Overview
Table 153. Alcami Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 154. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Alcami (2019-2024)
Table 155. Alcami Recent Developments
Table 156. Euroapi Basic Information List
Table 157. Euroapi Description and Business Overview
Table 158. Euroapi Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 159. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Euroapi (2019-2024)
Table 160. Euroapi Recent Developments
Table 161. Eurofins Basic Information List
Table 162. Eurofins Description and Business Overview
Table 163. Eurofins Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 164. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Eurofins (2019-2024)
Table 165. Eurofins Recent Developments
Table 166. Avid Bioservices Basic Information List
Table 167. Avid Bioservices Description and Business Overview
Table 168. Avid Bioservices Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 169. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of Avid Bioservices (2019-2024)
Table 170. Avid Bioservices Recent Developments
Table 171. BioVectra Basic Information List
Table 172. BioVectra Description and Business Overview
Table 173. BioVectra Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 174. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of BioVectra (2019-2024)
Table 175. BioVectra Recent Developments
Table 176. CPL Basic Information List
Table 177. CPL Description and Business Overview
Table 178. CPL Pharmaceutical CMO and CDMO Products, Services and Solutions
Table 179. Revenue (US$ Million) in Pharmaceutical CMO and CDMO Business of CPL (2019-2024)
Table 180. CPL Recent Developments
Table 181. Key Raw Materials Lists
Table 182. Raw Materials Key Suppliers Lists
Table 183. Pharmaceutical CMO and CDMO Downstream Customers
Table 184. Pharmaceutical CMO and CDMO Distributors List
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
Table 188. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Pharmaceutical CMO and CDMO Product Picture
Figure 2. Global Pharmaceutical CMO and CDMO Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 4. Pharmaceutical CMO and CDMO Report Years Considered
Figure 5. Global Pharmaceutical CMO and CDMO Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Pharmaceutical CMO and CDMO Revenue in 2023
Figure 7. Pharmaceutical CMO and CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. API CMO and CDMO Picture
Figure 9. FDF CMO and CDMO Picture
Figure 10. Packaging CMO Picture
Figure 11. Clinical CDMO Picture
Figure 12. Global Pharmaceutical CMO and CDMO Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 13. Global Pharmaceutical CMO and CDMO Sales Value Market Share by Type, 2023 & 2030
Figure 14. Product Picture of Pharmaceutical Company
Figure 15. Product Picture of Biotechnology Company
Figure 16. Product Picture of Other
Figure 17. Global Pharmaceutical CMO and CDMO Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Pharmaceutical CMO and CDMO Sales Value Market Share by Application, 2023 & 2030
Figure 19. North America Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 20. North America Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 22. Europe Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 24. Asia Pacific Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
Figure 25. South America Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 26. South America Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
Figure 27. Middle East & Africa Pharmaceutical CMO and CDMO Sales Value (2019-2030) & (US$ Million)
Figure 28. Middle East & Africa Pharmaceutical CMO and CDMO Sales Value by Country (%), 2023 VS 2030
Figure 29. Key Countries/Regions Pharmaceutical CMO and CDMO Sales Value (%), (2019-2030)
Figure 30. United States Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 31. United States Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 32. United States Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 33. Europe Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 34. Europe Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 35. Europe Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 36. China Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 37. China Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 38. China Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 39. Japan Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 40. Japan Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 41. Japan Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 42. South Korea Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 43. South Korea Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 44. South Korea Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 45. Southeast Asia Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 47. Southeast Asia Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 48. India Pharmaceutical CMO and CDMO Sales Value, (2019-2030) & (US$ Million)
Figure 49. India Pharmaceutical CMO and CDMO Sales Value by Type (%), 2023 VS 2030
Figure 50. India Pharmaceutical CMO and CDMO Sales Value by Application (%), 2023 VS 2030
Figure 51. Pharmaceutical CMO and CDMO Industrial Chain
Figure 52. Pharmaceutical CMO and CDMO Manufacturing Cost Structure
Figure 53. Channels of Distribution (Direct Sales, and Distribution)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Shielded Isolator Market Research Report 2025
Jan 25, 25
Global Compressor Nebulizers Market Research Report 2025
Jan 25, 25
Global Electric Mining Truck Market Research Report 2025
Jan 25, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232